Published January 31,2023
Subscribe
Pfizer, a key producer of coronavirus vaccines and a drug to combat Covid-19, expects income to sluggish this 12 months after posting file income in 2022, the corporate stated on Tuesday.
Revenues for 2022 have been $100.3 billion, an all-time excessive for the U.S. pharmaceutical firm. This included 30% in operational progress, the corporate stated in a press release. Last 12 months income rose by 43% to $31.3 billion.
Brisk gross sales of its Covid-19 treatment Paxlovid boosted gross sales, the agency stated.
But the corporate predicted 2023 income will increase would sluggish to $67 billion to $71 billion, as unfold of the coronavirus has slowed and plenty of nations are sitting on stockpiles of the vaccine and medicine.
Earnings per share (EPS) adjusted for particular components rose by 62% to $6.58. For 2023, Pfizer has set a goal vary of $3.25 to $3.45.
Source: www.anews.com.tr
